Nancy Bouvier

Publications (2)83.32 Total impact

• Source

  Available from: med-nexus.co.uk

  Article: KIT as a therapeutic target in metastatic melanoma.

  Richard D Carvajal, Cristina R Antonescu, Jedd D Wolchok, Paul B Chapman, Ruth-Ann Roman, Jerrold Teitcher, Katherine S Panageas, Klaus J Busam, Bartosz Chmielowski, Jose Lutzky, Anna C Pavlick, Anne Fusco, Lauren Cane, Naoko Takebe, Swapna Vemula, Nancy Bouvier, Boris C Bastian, Gary K Schwartz
  [show abstract] [hide abstract]
  ABSTRACT: Some melanomas arising from acral, mucosal, and chronically sun-damaged sites harbor activating mutations and amplification of the type III transmembrane receptor tyrosine kinase KIT. We explored the effects of KIT inhibition using imatinib mesylate in this molecular subset of disease. To assess clinical effects of imatinib mesylate in patients with melanoma harboring KIT alterations. A single-group, open-label, phase 2 trial at 1 community and 5 academic oncology centers in the United States of 295 patients with melanoma screened for the presence of KIT mutations and amplification between April 23, 2007, and April 16, 2010. A total of 51 cases with such alterations were identified and 28 of these patients were treated who had advanced unresectable melanoma arising from acral, mucosal, and chronically sun-damaged sites. Imatinib mesylate, 400 mg orally twice daily. Radiographic response, with secondary end points including time to progression, overall survival, and correlation of molecular alterations and clinical response. Two complete responses lasting 94 (ongoing) and 95 weeks, 2 durable partial responses lasting 53 and 89 (ongoing) weeks, and 2 transient partial responses lasting 12 and 18 weeks among the 25 evaluable patients were observed. The overall durable response rate was 16% (95% confidence interval [CI], 2%-30%), with a median time to progression of 12 weeks (interquartile range [IQR], 6-18 weeks; 95% CI, 11-18 weeks), and a median overall survival of 46.3 weeks (IQR, 28 weeks-not achieved; 95% CI, 28 weeks-not achieved). Response rate was better in cases with mutations affecting recurrent hotspots or with a mutant to wild-type allelic ratio of more than 1 (40% vs 0%, P = .05), indicating positive selection for the mutated allele. Among patients with advanced melanoma harboring KIT alterations, treatment with imatinib mesylate results in significant clinical responses in a subset of patients. Responses may be limited to tumors harboring KIT alterations of proven functional relevance. Trial Registration clinicaltrials.gov Identifier: NCT00470470.
  JAMA The Journal of the American Medical Association 06/2011; 305(22):2327-34. · 30.03 Impact Factor
• Article: Mutations in GNA11 in uveal melanoma.

  Catherine D Van Raamsdonk, Klaus G Griewank, Michelle B Crosby, Maria C Garrido, Swapna Vemula, Thomas Wiesner, Anna C Obenauf, Werner Wackernagel, Gary Green, Nancy Bouvier, M Mert Sozen, Gail Baimukanova, Ritu Roy, Adriana Heguy, Igor Dolgalev, Raya Khanin, Klaus Busam, Michael R Speicher, Joan O'Brien, Boris C Bastian
  [show abstract] [hide abstract]
  ABSTRACT: Uveal melanoma is the most common intraocular cancer. There are no effective therapies for metastatic disease. Mutations in GNAQ, the gene encoding an alpha subunit of heterotrimeric G proteins, are found in 40% of uveal melanomas. We sequenced exon 5 of GNAQ and GNA11, a paralogue of GNAQ, in 713 melanocytic neoplasms of different types (186 uveal melanomas, 139 blue nevi, 106 other nevi, and 282 other melanomas). We sequenced exon 4 of GNAQ and GNA11 in 453 of these samples and in all coding exons of GNAQ and GNA11 in 97 uveal melanomas and 45 blue nevi. We found somatic mutations in exon 5 (affecting Q209) and in exon 4 (affecting R183) in both GNA11 and GNAQ, in a mutually exclusive pattern. Mutations affecting Q209 in GNA11 were present in 7% of blue nevi, 32% of primary uveal melanomas, and 57% of uveal melanoma metastases. In contrast, we observed Q209 mutations in GNAQ in 55% of blue nevi, 45% of uveal melanomas, and 22% of uveal melanoma metastases. Mutations affecting R183 in either GNAQ or GNA11 were less prevalent (2% of blue nevi and 6% of uveal melanomas) than the Q209 mutations. Mutations in GNA11 induced spontaneously metastasizing tumors in a mouse model and activated the mitogen-activated protein kinase pathway. Of the uveal melanomas we analyzed, 83% had somatic mutations in GNAQ or GNA11. Constitutive activation of the pathway involving these two genes appears to be a major contributor to the development of uveal melanoma. (Funded by the National Institutes of Health and others.).
  New England Journal of Medicine 11/2010; 363(23):2191-9. · 53.30 Impact Factor